LCTX
Lineage Cell Therapeutics, Inc.
There isn't enough reported data to score LCTX yet.
LCTX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
LCTX's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LCTX PE Valuation
LCTX has no meaningful PE right now: it lost money over the past year.
LCTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCTX's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LCTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$0.12 | +$0.01 |
| Q2 2024 | -$0.14 | -$0.01 |
| Q1 2024 | -$0.14 | $0.00 |
| Q4 2023 | -$0.13 | +$0.02 |
| Q3 2023 | -$0.13 | +$0.16 |
| Q2 2023 | -$0.13 | +$0.17 |
| Q1 2023 | -$0.14 | +$0.15 |
| Q4 2022 | -$0.15 | +$0.11 |
LCTX is still losing money, but far less than before: $0.09 per share over the past year, against $0.40 at its worst in early 2020.
LCTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4M | -61% |
| Q2 2026 | $1.1M | -61% |
| Q1 2026 | $1.7M | +15% |
| Q4 2025 | $6.6M | +130% |
| Q3 2025 | $3.7M | -2.6% |
| Q2 2025 | $2.8M | +96% |
| Q1 2025 | $1.5M | +4% |
| Q4 2024 | $2.9M | +37% |
LCTX's revenue has held roughly level: $1M last quarter, down 61% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -510% | -407 points |
| Q2 2026 | -835% | -119 points |
| Q1 2026 | -440% | -7.1 points |
| Q4 2025 | -99% | +79 points |
| Q3 2025 | -103% | -1.2 points |
| Q2 2025 | -715% | -299 points |
| Q1 2025 | -433% | +28 points |
| Q4 2024 | -178% | +127 points |
LCTX's operating margin was −510% last quarter, down 407 points from the same quarter a year ago.
LCTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.7M | -$2.1M |
| Q2 2026 | -$7.4M | -$1.8M |
| Q1 2026 | -$8.1M | -$3.2M |
| Q4 2025 | -$5.3M | +$1.4M |
| Q3 2025 | -$3.6M | +$2.3M |
| Q2 2025 | -$5.6M | -$327K |
| Q1 2025 | -$5M | +$838K |
| Q4 2024 | -$6.7M | -$601K |
LCTX has burned cash in almost every quarter: −$26M over the past year, against −$21M the year before.
LCTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -2.4M shares |
| 1 year | +13% | +30.2M shares |
| 3 years | +52% | +88.5M shares |
| 5 years | +73% | +109M shares |
LCTX has 259M diluted shares, up 13% from a year ago.
LCTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -0.1x | Net Cash |
| Q2 2023 | -0.3x | Net Cash |
LCTX has more cash than debt.
LCTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.5 | Neutral |
| Stochastic | 39.4 | Neutral |
LCTX's weekly RSI is 40 (neutral) and its Stochastic is 39 (neutral).
LCTX PE vs Healthcare Sector
LCTX has no meaningful PE right now: it lost money over the past year.
LCTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.99 | 0% above |
| 20 week MA | $1.07 | 7.5% below |
| 50 week MA | $1.35 | 27% below |
| 100 week MA | $1.16 | 15% below |
| 200 week MA | $1.15 | 14% below |
LCTX is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
LCTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.77 | $1.76 | +129% |
| 2021 | $1.76 | $2.68 | +52% |
| 2022 | $2.68 | $1.09 | -59% |
| 2023 | $1.09 | $1.09 | 0% |
| 2024 | $1.09 | $0.50 | -54% |
| 2025 | $0.50 | $1.65 | +230% |
| 2026 YTD | $1.65 | $0.99 | -40% |
LCTX's yearly returns have swung widely, from +230% in 2025 to −59% in 2022. It's down 40% so far in 2026.